# Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Study · id `cardio:ct-nct03855826` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03855826](<https://clinicaltrials.gov/study/NCT03855826>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03855826

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 756 participants.

## Technical summary

Registry record NCT03855826. Randomized; no masking; primary purpose treatment. Start 2019-01-15 (actual); primary completion 2020-01-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 756 participants (planned count; ClinicalTrials.gov record NCT03855826, source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)
- Started: 2019-01-15 (actual) (ClinicalTrials.gov record NCT03855826, source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)
- Primary completion: 2020-01-30 (anticipated) (ClinicalTrials.gov record NCT03855826, source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)
- Completion: 2020-01-30 (anticipated) (ClinicalTrials.gov record NCT03855826, source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03855826, source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03855826-2019-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
- Condition: Ventricular Tachycardia
- Condition: Ventricular Fibrillation
- Intervention (Drug): Nifekalant hydrochloride
- Intervention (Drug): Amiodarone
- Lead sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry intervention name matches this record: Amiodarone (`cardio:amiodarone`)

## Provenance

Content hash: 39dcfee208d7304e23af5bcba178e7bfc26f5d680541341563c4140e6adeb5d1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
